SLC7A11 and colorectal carcinoma: As observed in the mouse CRC xenograft model, ESSENCE-high PDX tumors had reduced SLC7A11 and GPX4 expression in the selumetinib treatment group since ERK–ESSENCE–ferroptosis defense signaling is intercepted (Fig. 7F).